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Abstract: Chronic infections of Pseudomonas aeruginosa in the lungs of cystic fibrosis (CF) patients
are problematic in Ireland where inherited CF is prevalent. The bacteria’s capacity to form a biofilm
in its pathogenesis is highly virulent and leads to decreased susceptibility to most antibiotic
treatments. Herein, we present the activity profiles of the Cu(II), Mn(II) and Ag(I) tdda‐phen chelate
(Cu‐tdda‐phen),
{[Mn(3,6,9‐
complexes
{[Cu(3,6,9‐tdda)(phen)2].3H2O.EtOH}n
tdda)(phen)2].3H2O.EtOH}n (Mn‐tdda‐phen) and [Ag2(3,6,9‐tdda)(phen)4].EtOH (Ag‐tdda‐phen)
(tddaH2 = 3,6,9‐trioxaundecanedioic acid; phen = 1,10‐phenanthroline) towards clinical isolates of P.
aeruginosa derived from Irish CF patients in comparison to two reference laboratory strains (ATCC
27853 and PAO1). The effects of the metal‐tdda‐phen complexes and gentamicin on planktonic
growth, biofilm formation (pre‐treatment) and mature biofilm (post‐treatment) alone and in
combination were investigated. The effects of the metal‐tdda‐phen complexes on the individual
biofilm components; exopolysaccharide, extracellular DNA (eDNA), pyocyanin and pyoverdine are
also presented. All three metal‐tdda‐phen complexes showed comparable and often superior
activity to gentamicin in the CF strains, compared to their activities in the laboratory strains, with
respect to both biofilm formation and established biofilms. Combination studies presented
synergistic activity between all three complexes and gentamicin, particularly for the post‐treatment
of established mature biofilms, and was supported by the reduction of the individual biofilm
components examined.
Keywords: Pseudomonas aeruginosa; biofilm; metal complexes; 3,6,9‐trioxaundecanedioic acid; 1,10‐
phenanthroline

1. Introduction
Pseudomonas aeruginosa is a ubiquitous Gram‐negative human pathogen that can colonise a
diversity of sites with severe clinical consequences. Isolates of P. aeruginosa are found in nosocomial
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infections within immunocompromised patients, ranging from burn sepsis [1] to ventilator‐
associated pneumonia [2], to pulmonary infections of patients with lung afflictions such as cystic
fibrosis (CF) and chronic obstructive pulmonary disease (COPD) [3]. CF is an inherited autosomal
recessive disorder characterised by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene located on chromosome 7 that primarily affects the lungs. Of particular
concern in Ireland is the ΔF508 mutation, of which 1 in 19 Irish people are asymptomatic carriers [4].
Individuals with this mutated gene suffer from a defective chloride channel protein on the epithelial
cells of the lungs, causing an imbalance of chloride ions and fluid, and therefore the production of a
thick mucus and impaired mucociliary clearance of inhaled microbes, resulting in recurrent chronic
respiratory infections and inflammation. P. aeruginosa is the leading cause of infection in patients with
CF, and it is more prevalent in adults [5].
The prosperity of this microorganism is attributed to its biofilm forming capability and its vast
repertoire of cell‐associated and extracellular virulence factors controlled by transcriptional
regulators, which enables its swift adaptation to environmental changes and host defences. Biofilms
are structured multi‐cellular sessile communities, organized as micro‐colonies, encased within a self‐
produced extracellular matrix (ECM) that forms the scaffold for its three‐dimensional architecture
[6]. This porous and complex structure is composed of water and extracellular polymeric substances
which possess bacterial secreted biopolymers, such as polysaccharides, extracellular DNA (eDNA),
proteins, lipids, and metabolites such as pyocyanin and pyoverdine [7]. The formation of a biofilm is
a well‐regulated, multi‐step, endless cycle, including (i) initial reversible attachment of bacterial cells
with biotic or abiotic surfaces, followed by (ii) irreversible attachment within quick succession
leading to (iii) the development of the immature biofilm architecture as the bacteria undergoes
numerous physiological and phenotypic changes. The aggregation and accumulation of adherent
bacteria lead to (iv) the formation of multiple cell layers to form a mature biofilm with water channels
responsible for the distribution of nutrients and signalling molecules within the biofilm. Finally, due
to extrinsic or intrinsic factors, the bacteria (v) convert back to a planktonic state, to allow dispersal
of the cells and colonization in a new cycle of biofilm formation [8–10].
Conventional antibiotics are active against planktonic cells of P. aeruginosa that cause acute
infection, but often fail to completely eradicate their biofilms, leading to persistent infections. It is
well documented that pathogenic biofilms from patients demonstrate up to 1000‐fold reduced
susceptibility in comparison to their planktonic counterparts, due to the protective and altered nature
of the biofilm [11]. Formation of these aggregated communities with their inherent resistance to
antibiotics and host immune attack are at the root of many persistent and chronic bacterial infections.
For patients with CF who are infected with P. aeruginosa, antibiotic treatment often relieves the
symptoms, but does not necessarily cure the infection [12]. The acquisition of chronic P. aeruginosa
infection is associated with worsened disease progression and increased mortality. Moreover, the
effectiveness of the antibacterial agents to treat these pathogens is also compromised by the
emergence of multidrug‐resistant (MDR) strains, which highlights the urgent need for novel drugs
that can eradicate the robust biofilms of P. aeruginosa, by acting either alone or in tandem with other
clinical therapeutic interventions.
Over the past two decades, transition metal complexes have had a revival of interest as possible
alternatives or adjuvants to the current arsenal of antimicrobial agents, and in particular due to the
rapid emergence of resistant microorganisms occurring worldwide [13]. Novel inorganic complexes
with 1,10‐phenanthroline (phen) ligands have demonstrated promising therapeutic capabilities with
diverse biological activity, including anticancer [14,15], antifungal [16,17], antibacterial [18,19] and
antiviral [20] capabilities. In a recent review, we have reported on the research that points to the
potential of metal‐phenanthroline complexes as alternative therapeutics in this era of antibiotic
resistance [21]. For example, Viganor et al. [18] investigated the effect of phen, 1,10‐phenathroline‐
5,6‐dione (phendione) and the metal complexes [Cu(phendione)3]2+ and [Ag(phendione)2]+ on
planktonic‐ and biofilm‐growing clinical isolates of P. aeruginosa. The complexes and the metal free
phen and phendione ligands exhibited potency against susceptible and resistant planktonic cells in
the following order: [Cu(phendione)3]2+ (MIC = 7.76 μM) > [Ag(phendione)2]+ (MIC = 14.05 μM) >
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phendione (MIC = 31.15 μM) > phen (MIC = 579.28 μM). The pre‐treatment of the isolates with phen,
phendione and the metal‐phendione complexes at the 0.5 × MIC value inhibited biofilm formation,
significantly reducing both biomass and viability. The complexes could also disrupt an established
biofilm in a dose‐dependent manner. Further investigation demonstrated that the metal complexes
were effective inhibitors of the metalloenzyme Elastase B (lasB), suggesting this as a potential
therapeutic target [22]. In a more recent study, [Cu(phendione)3]2+ and [Ag(phendione)2]+ were also
shown to exhibit clinically relevant antimicrobial action against planktonic‐ and biofilm‐growing
cells of carbapenemase‐producing Acinetobacter baumannii clinical strains derived from hospital
patients in Brazil [23].
We have also recently evaluated the antimicrobial potential of a range of Cu(II), Mn(II) and Ag(I)
dicarboxylate‐phen chelate complexes against nine clinical isolates of three Candida haemulonii
species, an emerging opportunistic pathogen resistant to most current clinical antifungal drugs [17].
In that study, the Ag(I) chelates were shown to be the most effective drugs against planktonic cells
(overall geometric mean of the minimum inhibitory concentration (GM‐MIC) ranged from 0.26 to
2.16 μM), followed by the Mn(II) chelates (0.87–10.71 μM) and the Cu(II) chelates (3.37–>72 μM).
Although the same general level of activity was not maintained when the strains were tested during
a biofilm lifecycle of Candida haemulonii, the Mn(II) chelates with different dicarboxylate ligands
produced an overall geometric mean of the biofilm minimum inhibitory concentration (GM‐bMIC)
in the range 3.5–5.3 μM. Furthermore, the in vivo potential of the chelates to clear C. haemulonii
infections using the Galleria mellonella model revealed that the Mn(II)‐ and Ag(I)‐phen chelates were
able to conserve antifungal activity at concentrations that were reasonably non‐toxic toward G.
mellonella [24]. Most notable was {[Mn(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Mn‐tdda‐phen) (tddaH2 =
3,6,9‐trioxaundecanedioic acid), as it induced the lowest G. mellonella mortality rate while reducing
the fungal burden on infected larvae, and it also affected the virulence of C. haemulonii. Additionally,
the presence of the extremely hydrophilic 3,6,9‐trioxaundecanedioate ligand in the metal‐tdda‐phen
complexes considerably increased their water solubility when compared to that of the complexes
containing alternative aliphatic or aromatic dicarboxylate ligands.
Herein, we report the results of a further investigation into the antimicrobial activity of metal‐
tdda‐phen complexes. The complexes {[Cu(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Cu‐tdda‐phen),
{[Mn(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Mn‐tdda‐phen) and [Ag2(3,6,9‐tdda)(phen)4].EtOH (Ag‐
tdda‐phen) were tested on three clinical isolates of P. aeruginosa (CF1‐CF3), derived from Irish
hospital patients with CF, both alone and in combination with gentamicin, a well‐known antibiotic.
The results were compared to those derived for two established laboratory strains (ATCC 27853 and
PAO1). The effects on planktonic growth, as well as the inhibition of biofilm formation and biofilm
disarticulation, were assessed in terms of biofilm biomass and cell viability once treated. The anti‐
biofilm effects were further probed through an analysis of individual biofilm components, including
polysaccharides, eDNA and the virulence factors pyocyanin and pyoverdine, that help establish and
maintain the biofilm.
2. Results
2.1. The Inhibition of Planktonic Bacterial Growth by Metal‐tdda‐phen Complexes
Antimicrobial susceptibility testing of {[Cu(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Cu‐tdda‐phen),
{[Mn(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Mn‐tdda‐phen) and [Ag2(3,6,9‐tdda)(phen)4].EtOH (Ag‐
tdda‐phen), along with their phen‐free precursors, [Cu(3,6,9‐tdda)].H2O (Cu‐tdda), [Mn(3,6,9‐
tdda)(H2O)2].2H2O (Mn‐tdda) and [Ag2(3,6,9‐tdda].2H2O (Ag‐tdda), and their component synthetic
starting materials, 3,6,9‐trioxaundecanedioic acid (tddaH2), phen, the simple salts MnCl2, CuCl2 and
AgNO3, and the antibiotic gentamicin were evaluated through establishing their minimum inhibitory
concentration (MIC), in accordance with the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guidelines [25], and the results are summarised in Table 1. In accordance with the
EUCAST breakpoints, control strains ATCC 27853 and PAO1 were susceptible to the aminoglycoside
antibiotic gentamicin with MICs of 1 μg/mL (1.7 μM) and 2 μg/mL (3.5 μM), respectively, while all
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the clinical isolates were deemed resistant to the antibiotic. When all of the strains were incubated in
the presence of the Cu(II), Mn(II) and Ag(I) simple salts (effectively the free metal ions) or in the
presence of the metal‐free phen ligand, no clinically relevant effects against either control strains
(ATCC 27853 and PAO1) or clinical isolates (CF1‐CF3) were observed. A similar inactivity profile
was witnessed for the phen‐free precursor complexes, Cu‐tdda, Mn‐tdda and Ag‐tdda.
Table 1. Effects of test compounds on planktonic growth of P. aeruginosa laboratory strains (ATCC
27853 and PAO1) and clinical isolates (CF1–CF3).
Test Compound
Mn‐tdda
Cu‐tdda
Ag‐tdda
Mn‐tdda‐phen
Cu‐tdda‐phen
Ag‐tdda‐phen
Phen
tddaH2
MnCl2
CuCl2
AgNO3
Gentamicin

ATCC 27853
>256 (737)
>256 (848)
>256 (542)
16 (21.7)
16 (21.5)
8 (6.6)
128 (710)
>256 (1152)
>256 (1294)
>256 (1502)
128 (753)
1 (1.7)

MIC μg/mL and (μM)
PAO1
CF1
CF2
>256 (737)
>256 (737)
>256 (737)
128 (424)
>256 (848)
>256 (848)
>256 (542)
>256 (542)
>256 (542)
32 (43.5)
8 (10.9)
8 (10.9)
32 (43)
8 (10.7)
8 (10.7)
32 (26.6)
16(13.3)
16 (13.3)
>256 (1420)
128 (710)
128 (710)
>256 (1152) >256 (1152) >256 (1152)
>256 (1294) >256 (1294) >256 (1294)
>256 (1502) >256 (1502) >256 (1502)
256 (1507) >256 (1507) >256 (1507)
2 (3.5)
8 (13.9)
128 (222)

CF3
>256 (737)
256 (848)
>256 (542)
128 (174)
64 (86)
64 (53.2)
>256 (1420)
>256 (1152)
>256 (1294)
>256 (1502)
256 (1507)
>256 (445)

The metal‐tdda‐phen complexes were the most active against all of the P. aeruginosa strains
compared to their non‐phen precursors, simple metal salts and metal‐free phen. The three metal‐
tdda‐phen complexes all had different activity profiles across the strains. Of the control strains (ATCC
27853 and PAO1), gentamicin had the greatest inhibitory action (1–2 μg/mL) (1.7–3.5 μM), followed
by Ag‐tdda‐phen (8–32 μg/mL) (6.6–26.6 μM), with the least active being Cu‐tdda‐phen, and Mn‐
tdda‐phen (both had the same activity of ca. 16 and 32 μg/mL) (ca. 21 and 43 μM). In contrast to these
control strains, the metal‐tdda‐phen complexes were active against all of the CF clinical isolates.
Against CF1, these three metal complexes had activity (8–16 μg/mL) (10.9–13.3 μM) comparable to
that of gentamicin, and were more active than this antibiotic against CF2 (8–16 μg/mL) (10.9–13.3
μM) and CF3 (64–128 μg/mL) (53.2–174 μM). Following the MIC measurement, it was only the three
metal‐tdda‐phen complexes and gentamicin that were used in further biological assays.
2.2. Metal‐tdda‐phen Complexes Are Able to Inhibit Biofilm Formation and Disrupt Established Biofilm
Although bacteria are unicellular organisms, they exist in natural and clinical settings
predominately within biofilms. To determine the capacity of the test complexes to prevent the
formation of biofilms by P. aeruginosa isolates, bacterial cells were pre‐treated with the three metal‐
tdda‐phen complexes or gentamicin for 48 h. Similarly, the post‐treatment of established mature
biofilms (at 48 h) was also carried out to compare the effect of the compounds on developing or
developed biofilms. For both pre‐ and post‐treatment studies, cellular viability (resazurin stain) and
biofilm biomass (crystal violet stain) were measured. Both stains could be used sequentially on the
same treated biofilm sample, as resazurin measures only viable cells, whereby crystal violet binds to
the extracellular matrix of biofilms and stains all cells present in the biomass, with no discrimination
between live or dead cells. However, one limitation of the resazurin method is that it does not allow
for the detection of persister cells that may be present in the biofilm, and therefore was measured just
to accompany biofilm biomass data.
The pre‐treatment of potential biofilm‐forming bacterial cells with the metal‐tdda‐phen
complexes and gentamicin was dose‐dependent for both cellular viability (Figure 1) and biofilm
biomass (Figure 2), inhibiting biofilm formation at concentrations lower than the concentration
required to restrict planktonic bacterial growth, as previously outlined (Table 1), and with contrasting
activity between the laboratory strains and CF clinical isolates. Gentamicin was found to inhibit
biofilm formation in strains ATCC 27853 and PAO1, upwards of 50% at a concentration of 1.7 μg/mL
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(2.9 μM) and 1.9 μg/mL (3.3 μM), respectively, while it required 8.6–39.2 μg/mL (7.2–53.3 μM) of the
metal‐tdda‐phen complexes to illicit the same response. The activity of Mn‐tdda‐phen, Cu‐tdda‐phen
and Ag‐tdda‐phen varied across the clinical isolates, and were either comparable (CF1) or superior
to gentamicin (CF2 and CF3). For CF1, the biomass was inhibited 50% by Mn‐tdda‐phen at a
concentration of 4 μg/mL (5.4 μM), followed by gentamicin (4.2 μg/mL, 7.3 μM), Ag‐tdda‐phen (6.1
μg/mL, 5.1 μM) and Cu‐tdda‐phen (8.4 μg/mL, 11.3 μM). To inhibit biofilm formation by 50% in CF2,
2.5 μg/mL (3.4 μM) of Mn‐tdda‐phen, 4.4 μg/mL (5.9 μM) of Cu‐tdda‐phen, 6.2 μg/mL (5.2 μM) of
Ag‐tdda‐phen and 81.3 μg/mL (141.2 μM) of gentamicin were required, respectively, while for CF3,
which formed the strongest biofilm, 26.5 μg/mL (35.6 μM) of Cu‐tdda‐phen, 29.7 μg/mL (40.4 μM) of
Mn‐tdda‐phen, 33.4 μg/mL (27.8 μM) of Ag‐tdda‐phen and 116.5 μg/mL (202.4 μM) of gentamicin
were required to inhibit the biofilm formation by 50%. Interestingly, pre‐treatment of the clinical
isolates with sub‐MICs of gentamicin increased the biomass, relative to the untreated sample, which
has previously been observed [26]
As antibiotics are predominantly administered in clinical practice to counteract an existing
infection, evaluating the effects on established mature biofilms (post‐treatment) provided a more
pragmatic insight to the anti‐biofilm activity of the test complexes. None of the test complexes caused
the complete eradication of P. aeruginosa biofilms at the concentrations presented by cellular viability
(Figure 1) and biofilm biomass (Figure 2). The activity of gentamicin diminished considerably across
all strains when administered to established biofilms, a feature which has commonly been reported
[27]. While gentamicin maintained moderate activity against ATCC 27853, with the minimum biofilm
eradication concentration (MBEC) removing 50% of the biomass (MBEC50) being 19.6 μg/mL (34.1
μM), the MBEC50 for PAO1 was considerable larger (181 μg/mL, 314 μM). At the highest
concentration of gentamicin examined (256 μg/mL, 445 μM) against the clinical isolates CF1, CF2 and
CF3, there was still approximately 52%, 67% and 98% biofilm remaining, respectively, relative to the
untreated samples. It is well known that, as a mature biofilm is established, the extracellular matrix
slows or prevents the penetration of antibiotics into the microbial communities embedded in it.
Surprisingly, against the clinical isolates, the metal‐tdda‐phen complexes all showed similar activity
to each other (MBEC50 range ca. 12–51 μg/mL, 14–70 μM), and were superior to gentamicin.
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Figure 1. Cell viability—Effect of metal‐tdda‐phen complexes (Mn‐tdda‐phen, Cu‐tdda‐phen and Ag‐
tdda‐phen) and gentamicin on both inhibiting biofilm formation (pre‐treatment) and dismantling
established biofilms (post‐treatment) of laboratory strains (ATCC 27853 and PAO1) and clinical
isolates (CF1‐CF3).
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Figure 2. Biofilm biomass—Effect of metal‐phen complexes (Mn‐tdda‐phen, Cu‐tdda‐phen and Ag‐
tdda‐phen) and gentamicin on both inhibiting biofilm formation (pre‐treatment) and dismantling
established biofilms (post‐treatment) of laboratory strains (ATCC 27853 and PAO1) and clinical
isolates (CF1‐CF3). Asterisks indicate significance (p > 0.05) relative to the untreated control.

2.3. Metal–tdda–phen Complexes Enhanced the Anti‐biofilm Activity of Gentamicin
Biofilm‐associated tolerance is multifactorial and is attributed to restricted penetration of the
antimicrobial agent and the different metabolic states and virulence factors of the microbial
community within the biofilm. Current research approaches aimed at increasing the likelihood of
biofilm eradication include the use of non‐antibiotic complexes, either alone or in combination with

Antibiotics 2020, 9, 674

8 of 22

conventional antibiotics [28]. The combination of metal‐tdda‐phen complexes (0–64 μg/mL) with
gentamicin (0–32 μg/mL) was tested on established mature (48 h) biofilms of P. aeruginosa using the
checkerboard assay, and the results are presented in Figure 3 for all strains; ATCC 27853 (A–C), PAO1
(D–F), CF1 (G–I), CF2 (J–L) and CF3 (M–O). To varying degrees, the addition of the metal‐tdda‐phen
complexes enhanced the anti‐biofilm activity of gentamicin across all strains. At the highest
concentration of gentamicin alone (32 μg/mL, 55.5 μM), ca. 19–37% of the biofilm was removed from
reference strains ATCC 27853 and PAO1, whilst the same concentration of gentamicin, combined
with 4 μg/mL (3.3–5.4 μM) of the metal‐tdda‐phen complexes, was able to degrade over 50% of the
biofilm. Increasing the concentration of the added metal‐tdda‐phen complexes prompted the further
disintegration of the established biofilm. Most noteworthy, is the combination of the antibiotic with
Mn‐tdda‐phen and Ag‐tdda‐phen at 64 μg/mL (53.2 and 87 μM, respectively), which removed 99.6%
and 99.1% of PAO1 biofilm, respectively. Enhanced activity was also maintained across the clinical
isolates, with the combined metal‐tdda‐phen/gentamicin combinations presenting a dose‐dependent
response. At the highest test concentration, the combination of metal‐tdda‐phen complexes (64
μg/mL, 53.2–87 μM) with gentamicin (32 μg/mL, 55.5 μM) dismantled over 90% of the mature biofilm
for all three metal‐tdda‐phen complexes in CF2 (93.5–96.5% dismantled) and CF3 (93.9–99.6%), while
in CF1, the combination results were: Ag‐tdda‐phen (92.8%), Cu‐tdda‐phen (86.1%), Mn‐tdda‐phen
(83.1%).
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Figure 3. Heat map representation of percentage of biofilm removal of 48 h established biofilms of reference strains, ATCC 27853 and PAO1, and clinical isolates,
CF1‐CF3, by combinations of metal‐tdda‐phen complexes with gentamicin. Mn‐tdda‐phen and gentamicin (A,D,G,J,M); Cu‐tdda‐phen and gentamicin (B,E,H,K,N);
Ag‐tdda‐phen and gentamicin (C,F,I,L,O). Heat map shows the percentage of biofilm removed with respect to untreated sample.
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The fractional inhibitory concentration (FIC) index (FICI) for combinations of metal‐tdda‐phen
complexes with gentamicin was calculated according to the equation: FICI = FIC(metal‐tdda‐phen complex) +
FIC(gentamicin). Results for the interactions that occurred between the metal‐tdda‐phen complexes and
gentamicin combinations in the selected P. aeruginosa strains, PAO1 and CF3, are given in Table 2.
The data revealed synergistic activity (FIC ≤ 0.5) against the established mature biofilms for all of the
metal‐tdda‐phen/gentamicin combinations.
Table 2. Results of interaction studies for metal‐tdda‐phen/gentamicin combinations against PAO1
(reference strain) and CF3 (clinical isolate) in established biofilms.
Test complexes
Mn‐tdda‐phen + Gentamicin
Cu‐tdda‐phen + Gentamicin
Ag‐tdda‐phen + Gentamicin

Organism
PAO1
CF3
PAO1
CF3
PAO1
CF3

FIC Index
0.141
0.133
0.313
0.156
0.141
0.133

Interpretation
Synergy
Synergy
Synergy
Synergy
Synergy
Synergy

2.4. Metal‐tdda‐phen Complexes Reduce Components in a Biofilm; This Activity is Enhanced When
Combined with Gentamicin
In biofilms, microbes are held together by a protective polymeric extracellular matrix (ECM)
comprised of polysaccharides and extracellular DNA (eDNA), and also virulence factors such as
pyocyanin and pyoverdine. To understand how the metal‐tdda‐phen complexes effect both the
formation of biofilms (pre‐treatment) and the reduction of established mature biofilms (post‐
treatment), MBIC50 and MBEC50 doses were applied to P. aeruginosa strains PAO1 and CF3, alone and
in the presence of gentamicin, and the results are presented in Figure 4.
Exopolysaccharide is an important component of the ECM for the formation and stabilisation of
the biofilm structure, and therefore the reduction of this component would be a beneficial target for
antimicrobial agents. The pre‐treatment of PAO1 and CF3 with metal‐tdda‐phen complexes caused
an attenuation in exopolysaccharides. Exposure to Mn‐tdda‐phen caused the greatest reduction of
exopolysaccharide in PAO1 (74% ± 4), followed by Cu‐tdda‐phen (67% ± 1), Ag‐tdda‐phen (49% ± 6)
and gentamicin (47% ± 9). Combined pre‐treatment of Mn‐tdda‐phen, Cu‐tdda‐phen and Ag‐tdda‐
phen with gentamicin reduced exopolysaccharides in PAO1 by 64% ± 6, 72% ± 5 and 81% ± 5,
respectively, reducing the efficacy of Mn‐tdda‐phen as a single agent, but enhancing the effect of the
other two metal‐tdda‐phen complexes. Pre‐treatment of the clinical isolate CF3 with the test agents
saw a reduction in the activity of metal‐tdda‐phen complexes (52–55% ± 7) and gentamicin (38% ± 6)
against the exopolysaccharides, compared to that seen for PAO1. However, in contrast to PAO1, the
Mn‐tdda‐phen/gentamicin combination was the most effective (77% ± 1) at reducing
exopolysaccharide in the clinical isolate. For the post‐treatment studies, the biofilms were allowed to
grow for 48 h and then exposed to the test complexes for a further 24 h. For PAO1, the reduction of
exopolysaccharides by the metal‐tdda‐phen complexes (41–46% ± 9) was similar to that observed for
gentamicin (44% ± 9), while the combined treatment again intensified the activity, prompting a 73–
78% reduction in exopolysaccharide. For the treatment of CF3, gentamicin was the least effective and
Ag‐tdda‐phen the most when used singly (latter complex reduced the exopolysaccharide in the
biofilm by 61% ± 9). For the metal‐tdda‐phen/gentamicin combinations, activity increased somewhat
uniformly (72–77% reduction).
Extracellular DNA (eDNA) is recognised as an essential constituent of the ECM. It facilitates
biofilm formation and enhances biofilm strength and stability through the bridging by divalent ions
to other components in the matrix. It has also been observed that eDNA increases the tolerance of P.
aeruginosa biofilms toward cationic antibiotics, such as aminoglycosides, by binding directly to the
antibiotic and preventing penetration [29]. The pre‐treatment of PAO1 and CF3 with metal‐tdda‐
phen complexes or gentamicin singly did not cause any appreciable difference in eDNA content when
compared to the untreated sample. The combination treatments were unilaterally more effective,
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with Ag‐tdda‐phen/gentamicin inhibiting eDNA in PAO1 by 50% ± 11, Cu‐tdda‐phen/gentamicin by
49% ± 4 and Mn‐tdda‐phen/gentamicin 34% ± 6. A similar trend was observed for CF3. With the
exception of gentamicin, the post‐treatment of established biofilms of both strains with single metal‐
tdda‐phen complexes was more effective than pre‐treatment. A dramatic improvement in eDNA
inhibition was witnessed when both of the established biofilms were exposed to all of the metal‐tdda‐
phen/gentamicin combinations (66–75% reduction), with Cu‐tdda‐phen/gentamicin being the most
aggressive.
The prevalence and progression of infection by P. aeruginosa in the host is dependent upon the
secretion of numerous extracellular molecules, such as the virulent factors, pyocyanin and
pyoverdine. Pyocyanin is one of the major components dictating the advancement of infection and
biofilm formation, especially in CF patients, and is under quorum sensing (QS) control. It is redox
active and promotes eDNA release in P. aeruginosa by inducing cell lysis mediated via hydrogen
peroxide production. The extent of pyocyanin production varied amongst the strains of P. aeruginosa
tested, untreated PAO1 manufactured about 10 μM of pyocyanin, while the untreated CF clinical
isolate, CF3, produced upwards of 80 μM. The results of the pyocyanin assay are presented as a
percentage of production relative to the untreated sample for comparison (Figure 4). Pre‐treatment
with the Ag‐tdda‐phen/gentamicin combination effected the greatest reduction in pyocyanin in both
PAO1 (80% ± 9) and CF3 (65% ± 6). The manganese and copper metal‐tdda‐phen/gentamicin
combinations also reduced pyocyanin production when compared to their treatment as a single
agent. Surprisingly, the pre‐treatment of PAO1 with Cu‐tdda‐phen alone actually enhanced the
production of pyocyanin (106% ± 8), and gentamicin also had a similar positive influence on CF3
(116% ± 13). In general, the single test compounds and their gentamicin combinations were much less
effective at reducing pyocyanin production by the two mature biofilms. Although Ag‐tdda‐phen
alone increased pyocyanin in PAO1 (134%), it was the Ag‐tdda‐phen/gentamicin combination that
caused the greatest reduction of pyocyanin (35% ± 9 in PAO1 and 49% ± 7 in CF3).
Pyoverdine, the main siderophore of P. aeruginosa, has a high affinity for ferric (Fe3+) iron and
thus is responsible for obtaining extracellular iron, which is an essential nutrient for biofilm formation
[30]. In addition, pyoverdine can regulate the production of multiple bacterial virulence factors. In
the pre‐treatment studies (Figure 4), it was found that only the Ag‐tdda‐phen/gentamicin caused a
notable reduction in pyoverdine production (by 16% ± 5 in PAO1 and 49% ± 6 in CF3), with most of
the remaining test substances actually enhancing production (by up to 134%). Post‐treatment of the
two established biofilms with the single metal‐tdda‐phen compounds had little or no effect on
pyoverdine production with respect to the control. Whilst gentamicin singly and the Mn‐tdda‐
phen/gentamicin combination caused a sizable reduction in pyoverdine in the reference strain (24%
± 8 and 26% ± 9, respectively) and the clinical isolate (30% ± 8 and 41% ± 9, respectively), Cu‐tdda‐
phen/gentamicin and Ag‐tdda‐phen/gentamicin were only effective against CF3 (41% ± 9 and 48% ±
7 reduction, respectively).
In addition to the components of the biofilm, the liquid culture they were grown in was
aspirated, and the bacterial cells present were assessed through the plate count method. As presented
in Figure 5, untreated PAO1 had a 7.6 × 108 colony forming unit (CFU)/mL, while pre‐treatment with
metal‐tdda‐phen complexes saw a slight reduction of 7.1–5.2 × 108 CFU/mL, and gentamicin had 3.9
× 108 CFU/mL. Complementing the biofilm component data, the combination of both the metal‐tdda‐
phen complexes with gentamicin saw the greatest reduction of viable cells, with Ag‐tdda‐phen
demonstrating a one‐fold reduction, to 7.9 × 107 CFU/mL. Pre‐treatment of CF3 with gentamicin
reduced the viable cells from 7.5 × 108 CFU/mL to 7 × 108 CFU/mL, followed by Cu‐tdda‐phen (5.9 ×
108 CFU/mL), Ag‐tdda‐phen (5.5 × 108 CFU/mL) and Mn‐tdda‐phen (5.4 × 108 CFU/mL). Akin to
PAO1, metal‐tdda‐phen/gentamicin reduced viable cells in the culture to 3.3 × 108 CFU/mL–2.2 × 108
CFU/mL. Post‐treatment of PAO1 and CF3 had similar trends, metal‐tdda‐phen complexes as
singular agents slightly outperforming gentamicin. However, the combination of Mn‐tdda‐
phen/gentamicin and Cu‐tdda‐phen/gentamicin saw a 2‐fold reduction in viable cells and Ag‐tdda‐
phen/gentamicin a 3‐fold reduction.
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Figure 4. Effects of metal‐tdda‐phen complexes alone, gentamicin alone, and metal‐tdda‐phen
complexes with gentamicin on both the formation of biofilm (pre‐treatment) and reduction of
established biofilm (post‐treatment) of PAO1 and CF3: The percentages of exopolysaccharide, eDNA,
pyocyanin and pyoverdine remaining after treatment (relative to untreated biofilms) are given.
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Figure 5. Viable cells were measured after pre‐ and post‐ exposure to 0.5 × MBIC and 0.5 × MBEC of
metal‐tdda‐phen complexes alone, gentamicin alone, and metal‐tdda‐phen complexes with
gentamicin. The results are the means ± standard errors of the means from three independent
experiments, with viable counts done in triplicate.

3. Discussion
Pseudomonas aeruginosa is the most prevalent pathogen in the lungs of cystic fibrosis (CF) patients
and the leading cause of morbidity and mortality [12]. Ireland has the highest rate of CF per capita in
the world, with approximately 7 in every 10,000 people living with the disease; almost three times
the average rate in other European countries and the United States [31]. Conventional antibiotic
treatment strategies for P. aeruginosa in CF patients are only partially effective and contribute to
antibiotic resistance. P. aeruginosa predominantly reside in biofilms in the lungs of CF patients, which
are also up to 1000 times more resistant to antibiotic treatment than their planktonic counterparts.
Antibiotic treatment strategies are still being trialled and optimized for CF patients, and there have
been numerous studies comparing mono‐ and combination‐antibiotic therapies [32,33]. Amongst the
many alternative therapeutic approaches documented are the guluronate polymer OligoG (derived
from alginate), a simple thiol cysteamine, a novel synthetic peptide, nitric oxide and gallium(III)
compounds [34]. Ga3+ metal ions have been shown to disrupt biofilm formation and protect against
P. aeruginosa infections in vitro in human serum [35], mouse models [36,37] and humans [38].
Moreover, there is a decreased likelihood that P. aeruginosa can develop resistance to gallium
compared to the classic small molecule antibiotics [39]. Additional studies showed that co‐
encapsulation of Ga3+ with gentamicin in liposomes was more effective than gentamicin alone for
eradicating P. aeruginosa in both planktonic and biofilm forms [40]. There is clearly scope for the
development of novel metal complexes, either acting alone or in combination with antibiotics, as a
new therapeutic regime for P. aeruginosa infections in CF patients.
We have investigated the anti‐biofilm capabilities of copper(II), manganese(II), and silver(I)
complexes containing 1,10‐phenanthroline (phen) and 3,6,9‐trioxaundecanedioate (tddaH2) ligands,
for their ability to inhibit the planktonic growth of P. aeruginosa strains isolated from the lungs of CF
patients in Irish hospitals. These metal complexes have previously shown anti‐bacterial and anti‐
fungal capabilities, and the inclusion of the phen ligand is key to their antimicrobial properties.
Furthermore, the tdda dianionic ligand greatly enhances the water solubility of the complex. The
results presented in Table 1 clearly demonstrate the superior potency of the metal‐tdda‐phen
complexes when compared to the anti‐P. aeruginosa activities of the metal‐free phen, tddaH2 and the
simple copper(II), manganese(II) and silver(I) salts (essentially free metal ions). The antibiotic,
gentamicin, was the most active compound against the reference strains (ATCC 27853 and PAO1).
Whereas the efficacy of gentamicin dampened across the clinical isolates (CF1–CF3), the metal‐tdda‐
phen complexes maintained clinically relevant activity. Taking the mean minimum inhibitory
concentration (MIC) for each bacterial strain, the order of planktonic growth inhibition by the metal‐
tdda‐phen complexes was: Cu‐tdda‐phen > Ag‐tdda‐phen > Mn‐tdda‐phen. Gandra et al. [17]
reported that the Mn‐tdda‐phen complex was extremely well tolerated by the mammalian lung cell
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line, A549, with a concentration capable of reducing cellular viability by 50% (CC50) of 261.67 mg/L.
In the present study, the MIC range for Mn‐tdda‐phen was 8–128 μg/mL, suggesting that this
complex would be significantly selective for the CF1 and CF2 clinical strains of P. aeruginosa.
Furthermore, at the highest concentration of Mn‐tdda‐phen required to inhibit CF3 growth, the
complex would still have moderate selectivity.
The biofilm lifecycle of P. aeruginosa is an important virulence attribute for establishing infections
in CF patients. All of the metal‐tdda‐phen complexes were able to inhibit biofilm formation (pre‐
treatment) in terms of both biofilm biomass and cellular viability, outperforming gentamicin across
the three clinical isolates. Moreover, all three of the metal‐tdda‐phen complexes were able to disrupt
the established mature biofilm (post‐treatment) of the P. aeruginosa strains in a dose‐dependent
manner. Similar activity has previously been reported by Viganor et al. [18] for the related complex
cations, [Ag(phendione)2]+1 and [Cu(phendione)3]+2 (phendione = 1,10‐phenanthroline‐5,6‐dione),
against 32 Brazilian clinical isolates of P. aeruginosa. Moreover, the same phendione complexes were
shown to exhibit anti‐biofilm action against carbapenemase‐producing Acinetobacter baumannii,
another multi‐drug resistant (MDR) Gram‐negative bacterium [23]. Presently, the MIC of Mn‐tdda‐
phen for CF3 was 128 μg/mL (174 μM), and when an established biofilm of this strain is treated at the
same concentration, it is reduced by ~79%. The MIC of both Cu‐tdda‐phen and Ag‐tdda‐phen was 64
μg/mL (86 and 53.2 μM, respectively) for CF3, and the reduction in biofilm biomass after treatment
at this concentration was ~70% and ~51%, respectively. These anti‐biofilm studies indicated that there
is potential for enhanced anti‐biofilm activity, through a combination of the metal‐tdda‐phen
complexes with gentamicin. At the highest concentration of the metal‐tdda‐phen complexes (64
μg/mL) in combination with gentamicin (32 μg/mL), there was >90% biofilm removal for CF2 and
CF3 and >83% for CF1, and the fractional inhibitory concentration (FIC) index showed a positive
synergism for all three metal‐tdda‐phen complexes in the presence of gentamicin. A recent clinical
study in Ireland on cystic fibrosis P. aeruginosa clinical isolates with the same laboratory reference
strains (ATCC 27853 and PAO1) showed that tobramycin (aminoglycoside) and ceftazidime
(cephalosporin) was the only effective combination to show positive synergism (FIC ≤ 0.5) against a
mature biofilm of a single clinical isolate at a concentration of 64 mg/L [41]. However, as mentioned
earlier, the evolving resistance to antibiotics is problematic and of concern when considering
combinations of established antibiotics for the treatment of P. aeruginosa infections in CF patients.
Novel therapeutics, where resistance is less likely to be a factor, would be favourable for future
clinical interventions.
Since significant activity was evident for the metal‐tdda‐phen complexes, acting either alone or
in combination with gentamicin, against biofilms formed by the PAO1 reference strain and the CF3
clinical isolate, individual components of the biofilm were tested to see if there was a specific
molecular target. These targets included exopolysaccharide and extracellular DNA (eDNA), which
are two key components of the polymeric extracellular matrix (ECM), and the virulence factors,
pyocyanin and pyoverdine, which are found in the ECM. Many P. aeruginosa strains are capable of
synthesizing the three exopolysaccharides, alginate, Psl, and Pel, which play an important role in
biofilm formation and the stabilization of its structure. Strains isolated from CF patients are
commonly found to over‐produce alginate, and biofilms of these strains have been observed to have
a much higher resistance to aminoglycosides, such as gentamicin, than their isogenic non‐mucoid
strain [42]. Additional studies have also implicated both Psl [43] and Pel [44] in the biofilm‐associated
tolerance towards aminoglycosides, thus making exopolysaccharides an important component of the
ECM. It is thought that Psl associates with eDNA through hydrogen bonding to form eDNA–Psl
fibres in the centre of pellicles [45], and cationic Pel cross‐links eDNA in the biofilm stalk via ionic
interactions [46]. eDNA is known to chelate divalent metal cations, such as Mg2+, Mn2+, Zn2+ and Ca2+
[47], with the latter creating strong electrostatic interactions which give the biofilm integrity [48], and
there have been biofilm studies conducted on the use of metal chelators, such as
ethylenediaminetetraacetic acid (EDTA). In this context, EDTA alone was found to be 1000‐fold more
destructive to a PAO1 biofilm than gentamicin and, furthermore, a combination of EDTA (50 mM)
with gentamicin (50 μg/mL) caused a complete reduction of biofilm viability (>99%) and detachment
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of cells [49]. The present study demonstrated that the enhanced anti‐biofilm activity of metal‐tdda‐
phen/gentamicin combinations was associated with a reduction in both exopolysaccharide and
eDNA. It has been widely reported that the treatment of P. aeruginosa biofilms with DNase I, an
enzyme that cleaves DNA, significantly disrupts biofilms and enhances antibiotic penetration [50].
As CF sputum is rich in eDNA (<1–20 mg/mL), this is thus a desirable molecular target. The copper(I)
complex cation, [Cu(phen)2]+, in the presence of reducing agents, was the first reported example of a
novel artificial metallonuclease possessing potent DNA cleavage capability [51]. Our group has
previously shown that copper(II)‐dicarboxylate‐phen complexes also display effective nuclease
capability, even in the absence of added reductant [52]. In this context, treating a mature biofilm with
Cu‐tdda‐phen prompted the greatest decrease in eDNA in both the reference and clinical isolates.
Our data suggest that the metal‐tdda‐phen complexes cause biofilm destabilization by interacting
with extracellular DNA and exopolysaccharide in the ECM, possibly through Psl. However, further
studies will be required to establish the role of Psl and Pel in these interactions. This destabilization
could allow the previously inhibited gentamicin into the biofilm to enhance its cytotoxic action, which
has been further supported by the viable cell counts.
Pyocyanin and pyoverdine are both virulence factors and are carefully controlled by quorum
sensing networks. Pyocyanin is a metabolite involved in redox reactions in the biofilm, and
pyoveridine is the main siderophore of P. aeruginosa involved in iron metabolism. Both virulence
factors were reduced upon treatment with metal‐tdda‐phen/gentamicin combinations, but to a lesser
extent than the exopolysaccharide and eDNA. The encouraging results obtained from this study
prompt further investigations into more fully elucidating the exact mechanism(s) of action of the
metal‐tdda‐phen complexes and their gentamicin combinations. Furthermore, investigations of
combinations of the metal complexes with other antibiotics are also warranted.
4. Materials and Methods
4.1. Test Complexes
The metal complexes used for this study were originally synthesised by McCann et al. [53] as
follows: [Cu(3,6,9‐tdda)].H2O (Cu‐tdda) and {[Cu(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Cu‐tdda‐phen);
[Mn(3,6,9‐tdda)(H2O)2].2H2O (Mn‐tdda) and {[Mn(3,6,9‐tdda)(phen)2].3H2O.EtOH}n (Mn‐tdda‐phen)
and [Ag2(3,6,9‐tdda].2H2O (Ag‐tdda) and [Ag2(3,6,9‐tdda)(phen)4].EtOH (Ag‐tdda‐phen). The metal
complexes were prepared in accordance with those described by Gandra et al. [17].
In order to establish that the observed biological effects were due to the discrete complexes
rather than their free ligands, 1,10‐phenathroline (phen) and 3,6,9‐trioxaundecanedioic acid (tddaH2),
and metal salts, manganese chloride (MnCl2), copper chloride (CuCl2), and silver nitrate (AgNO3)
were also assessed (all chemicals were purchased from the Sigma‐Aldrich company and used without
further purification). The aminoglycoside antibiotic, gentamicin (Sigma‐Aldrich) was also
incorporated into the study, as it is an antibacterial agent commonly used to treat P. aeruginosa in
infected CF patients. All stock complexes (10 mg/mL) were diluted in tryptic soy broth (TSB) media
for desired test concentrations.
4.2. Bacterial Strains and Culture Conditions
Clinical isolates of Pseudomonas aeruginosa (CF1, CF2 and CF3), from cystic fibrosis patients at
local Irish hospitals, along with standard laboratory strains ATCC 27853 and PAO1, were obtained
from Dr. Gordon Cooke, Department of Science TU Dublin—Tallaght campus. ATCC 27853
originated from a blood culture in Boston, USA [54] while PAO1 originated form a burn wound in
Melbourne, Australia [55]. Stock frozen cultures were maintained at −80 °C in 20% (v/v) glycerol
solutions in tryptic soy broth (TSB; Lab M). Frozen cultures were streaked onto plates of tryptic soy
agar (TSA; Lab M) and incubated overnight at 37 °C. A single colony of bacteria was then inoculated
into TSB (50 mL) to prepare the bacterial inoculate for the experiments (37 °C at 200 rpm). Bacterial
cell suspensions of 106 CFU/mL were used for all subsequent experiments.
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4.3. Antimicrobial Susceptibility Testing of Complexes on Pseudomonas Aeruginosa Strains
4.3.1. Effects of Test Compounds on Planktonic Bacteria
All metal complexes and controls were tested for their activity on the clinical isolates (CF1–CF3)
and laboratory strains (ATCC 27853 and PAO1) of P. aeruginosa, using the standard broth micro–
dilution method to establish their minimum inhibitory concentration (MIC). The test complexes were
two–fold serially diluted and mixed with equal volumes (100 μL) of diluted bacteria in 96‐well plates
(Cruinn), thus making a final concentration range of the complexes tested, and included the antibiotic
control gentamicin, between 0.5 and 256 μg/mL. The MIC measurements were recorded on the basis
of turbidity according to EUCAST guidelines [56], after 16–18 h of incubation at 37 °C with agitation.
4.3.2. Effects of Test Compounds on Biofilm Formation (Pre‐treatment)
The activity of all complexes and controls on biofilm formation of all P. aeruginosa strains were
tested by measuring cellular viability and the total biomass in the cell culture wells. For both assays,
100 μL of the bacterial culture (made up in TSB medium) was distributed into each well of flat‐
bottomed 96–well polystyrene microtitre plates (Cruinn) and incubated for 48 h at 37 °C in the
presence of all test compounds (100 μL), administered at a concentration range of 0.5–256 μg/mL. The
supernatants from each well were removed, and the wells were then washed three times with
phosphate buffered saline (PBS). Viable cells in the biofilm were assessed by a fluorometric assay that
measures the metabolic capacity of cells [57]. TSB (250 μL) containing 5% (v/v) resazurin (Sigma‐
Aldrich) was added to the plates and incubated for 20 min at 37 °C. Fluorescence was then measured
at λexcitation = 560 nm and λemission = 590 nm, with a Varioskan LUX (Thermo Scientific) microplate
reader. Then, the resazurin stain was removed and replaced by 250 μL of 0.1% (w/v) crystal violet
solution on the same plate [58] to evaluate biofilm biomass. After 20 min, the crystal violet stain was
removed, and the wells werewashed three times. The wells were dried and 250 μL of 30% acetic acid
(Sigma–Aldrich) was added to release the bound crystal violet. Absorbance was measured on a
Multiskan GO (Thermo Scientific) microplate reader at 590 nm.
4.3.3. Effects of Test Compounds on the Mature Biofilm (Post‐treatment)
In addition to testing the effects of the metal‐tdda‐phen complexes on biofilm formation (pre‐
treatment) of the P. aeruginosa strains, their ability to weaken an established biofilm was also assessed
with the post‐treatment of mature biofilms. Moreover, 100 μL of the bacteria culture (in TSB) was
added to each well of flat bottomed 96–well polystyrene microtitre plates (Cruinn) and incubated for
48 h at 37 °C, to allow for biofilm formation. After 48 h incubation, the test complexes and control
were added over a range of concentrations (0.5–256 μg/mL) to mature biofilms and incubated for an
additional 24 h. To the untreated control, 100 μL of fresh media was added to the wells. Cellular
viability and biofilm biomass were measured using resazurin staining and crystal violet staining, as
previously described in Section 4.3.2.
4.3.4. Checkerboard Assay for Mature Biofilms
The anti‐biofilm activity of individual metal‐tdda‐phen complexes alone and in combination
with gentamicin were evaluated against the P. aeruginosa strains using the broth micro‐dilution
checkerboard technique [59]. Mature biofilms were prepared as previously described in Section 4.3.3.
The preformed biofilms in the wells of separate 96‐well microtitre plates were rinsed with PBS and
100 μL of the metal‐tdda‐phen complexes and gentamicin (two‐fold serial dilutions); each was added
to the wells containing the biofilms. Following incubation for 24 h at 37 °C, the biofilm biomass and
cell viability were measured as previously described.
The fractional inhibitory concentration (FIC) index (FICI) for combinations of testing agents was
calculated for selected P. aeruginosa strains PAO1 and CF3, according to the equation: FICI = FIC(metal‐
tdda‐phen complex) + FIC(gentamicin). Where, FIC(metal‐tdda‐phen complex) = (MBEC* of metal‐tdda‐phen complex in
combination with gentamicin)/(MBEC* of metal‐tdda‐phen complex alone) and FIC(gentamicin) = (MBEC*
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of gentamicin in combination with metal‐tdda‐phen complex)/(MBEC* of gentamicin alone). These
strains were selected due to their contrasting activity profiles observed in the previous tests, and
because they formed the strongest biofilms (evidenced by crystal violet staining). The following
criteria were used to interpret the FICI: ≤0.5 synergy; 0.5–4.0 indifferent; >4.0 antagonism. *The
minimum biofilm eradication concentration (MBEC) was defined as the minimal concentration of the
compound required to eradicate the biofilm.
4.4. Effects of Test Complexes on Individual Components of Biofilm
Selected P. aeruginosa strains, PAO1 and CF3, were incubated in the presence and absence of
metal‐tdda‐phen complexes, alone and in combination with gentamicin. To assess the effects of
biofilm formation (pre‐treatment), experiments were set up according to Section 4.3.2 with strains
pre‐treated to 0.5 × minimum biofilm inhibitory concentration (MBIC). To assess the effects on
established mature biofilms (post‐treatment), experiments were set up according to Section 4.3.3,
with biofilms grown to 48 h, then treated with 0.5 × minimum biofilm eradication concentration
(MBEC) for a further 24 h. The bacterial cultures were harvested and the subsequent components,
including exopolysaccharide, extracellular DNA (eDNA), pyocyanin and pyoverdine, which were
analysed by the different methods described below.
4.4.1. Extraction and Quantification of Exopolysaccharide
Extraction and quantification of exopolysaccharide were performed by using a modified
protocol of Tribedi and Sil [60]. Biofilms were grown on a glass surface and then extracted by gentle
dislodgment using a cell scrapper (25 cm, Sarstedt) and PBS. The biofilm suspension was centrifuged
at 4500 g for 15 min and the supernatant was collected. The resulting pellet was treated with 10 mM/L
EDTA, vortexed and centrifuged again to extract cell‐bound polysaccharide. The supernatant was
harvested and mixed with the first harvested supernatant. An equal volume of chilled absolute
ethanol was added to the pooled supernatant and incubated at −20 °C for 1 h. After centrifugation at
10,000 g for 10 min, the pellet was resuspended in sterile water and measured by the phenol‐sulphuric
acid extraction method [61]. Briefly, 1 mL of the precipitated exopolysaccharide solution was mixed
with an equal amount of chilled phenol (5%) and 5 mL of concentrated sulphuric acid. The resulting
red colour was measured at 490 nm on a spectrophotometer (Hach, Bio‐Sciences).
4.4.2. Extraction and Quantification of Extracellular DNA (eDNA)
Extracellular DNA (eDNA), a key component of the biofilm, was extracted from the matrix using
a modified enzymatic method, as reported by Wu and Xi [62]. To release the eDNA from the matrix,
the biofilms were first exposed to cellulase (10 μg/mL, Novozymes) and α‐amylase (10 μg/mL, Sigma‐
Aldrich) to hydrolyse the polysaccharides, and incubated at 50 °C for 30 min [63,64]. Proteinase K (5
μg/mL, Sigma‐Aldrich) was then added to the mixture for a further 30 min, to degrade proteins, and
the supernatant was sequentially filtered through a 0.45 μm and then a 0.20 μm filter to remove
residual bacteria. The eDNA was precipitated by 1 volume of cetyltrimethylammonium bromide
(CTAB, Sigma‐Aldrich) solution (1% CTAB in 50 mM Tris–10 mM EDTA, pH 8.0), incubated at 65 °C
for 30 min, followed by centrifugation at 5000 g for 10 min. Each pellet was resuspended in high‐salt
TE buffer (10 mM Tris‐HCL, 0.1 mM EDTA, 1 M NaCl, pH 8.0) and 0.7 volume of cold isopropanol,
and incubated at −20 °C for 3 h. After centrifugation at 10,000 g for 15 min, pellets were suspended in
TE buffer (10 mM Tris‐HCL, 0.1 mM EDTA, pH 8.0) and an equal volume of equilibrated
phenol:chloroform:isoamyl alcohol (25:24:1) and centrifuged again. The upper aqueous layer was
transferred to a tube with an equal volume of chloroform:isoamyl alcohol (24:1) and centrifuged
again. The supernatant was then precipitated with 2 volumes of cold ethanol (70%) and one tenth the
final volume of sodium acetate (0.3 M), incubated at −20 °C for 1 h and centrifuged at 10,000 g for 15
min. The pellets were finally washed twice with ethanol and resuspended in MilliQ water. The purity
of the DNA was checked by determining the ratio of absorbance at 260 nm and 280 nm (A260/280)
using a MultiskanTM GO (Thermo Scientific) UV spectrophotometer with the μDrop plate, and the
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DNA was quantified fluorometrically (Qubit 3.0 Fluorometer, Invitrogen) by using SYBR Green I
(Molecular Probes), as described by Zipper [65]. The size of extracellular DNA was analyzed on a 1%
(w/v) agarose gel in a Tris‐Borate‐EDTA (TBE) buffer.
4.4.3. Quantification of Pyocyanin
Pyocyanin is a toxic, QS‐controlled metabolite produced by P. aeruginosa enabling biofilm
formation. After a 48 h incubation, the bacterial strains were centrifuged at 4500 g for 20 min and the
cell‐free supernatant was used. Pyocyanin from the supernatant was extracted and measured by the
methods of Essar et al. [66]. Then, 5 mL of filtered culture supernatant was extracted with chloroform
(3 mL), vortexed and centrifuged at 4500 g for 15 min. The chloroform phase was transferred to a
fresh tube with 1 mL of 0.2 M hydrochloric acid (HCL). After centrifugation at 4500 g for 4 min, the
top layer was collected and its absorption was measured on a spectrophotometer (Hach, Bio‐Sciences)
at 520 nm. Pyocyanin concentrations, expressed as micrograms per millilitre (μg/mL) of culture
supernatant, were determined by multiplying the OD at 520 nm by 17.072 (extinction coefficient).
4.4.4. Quantification of Pyoverdine
Pyoverdine is the main siderophore of P. aeruginosa, deployed in severely iron‐limited
environments, to assure sufficient supply of this essential nutrient, and is found at increased
concentrations in biofilms. After a 48 h incubation, the bacterial strains were centrifuged at 4500 g for
20 min and the cell‐free supernatant was used to measure pyoverdine. The relative concentration of
pyoverdine in all treated supernatant with respect to control was measured through florescence at
an excitation wavelength of 405 nm and an emission wavelength of 465 nm [67], with a Varioskan
LUX (Thermo Scientific) microplate reader.
4.4.5. Quantification of Bacteria
In addition to the components of the biofilm, liquid medium with bacteria was collected and
centrifuged (4500 g for 20 min), after which the supernatant was discarded, and the pellet was
resuspended in 1 mL PBS. Ten‐fold serial dilutions of the resuspended bacteria were then prepared
and plated on nutrient agar utilising the Miles and Misra (20 μL drop) method. Agar plates were
incubated at 37 °C for 16–18 h, after which colony forming unit (CFU) per mL was calculated using
the formula: CFU/mL = average number of colonies for a dilution × 50 × dilution factor.
4.5. Statistics
All experiments were performed in triplicate, in three independent experimental sets. All data
were statistically analysed using one‐way analysis variance (ANOVA). The data are expressed as
mean values with standard deviations (SDs). Data with p‐values smaller than 0.05 were considered
statistically significant. All statistical analyses were performed using GraphPad Prism (GraphPad
Software Inc., USA).
5. Conclusions
Cu(II)‐, Mn(II)‐ and Ag(I)‐tdda‐phen chelate complexes enhance the effects of gentamicin for
eradicating clinical P. aeruginosa‐established biofilms, originating from CF patients with individual
response and resistance profiles, and therefore offer an alternative combination therapeutic approach
with greater efficacy.
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